Rate My Professor Christopher Oldmeadow

Oldmeadow's research focuses on genetic epidemiology, Bayesian statistics, model selection, genomic segmentation, causal modelling, stroke, dementia, smoking cessation, colorectal cancer screening, Aboriginal health, implementation strategies, health behaviors post-stroke, medication safety in dementia, diabetes management, heart failure, musculoskeletal pain, opioid agonist treatment, and cardiovascular disease. He has published first-author articles in Molecular Biology and Evolution, Bioinformatics, and Genetic Epidemiology, and co-authored in Science and Nature Genetics. Notable works include 'Polygenic prediction of educational attainment within and between families from genome-wide association analyses in 3 million individuals' (Nature Genetics, 2022), 'The power of genetic diversity in genome-wide association studies' (Nature Genetics, 2021), 'Trans-ethnic association study of blood pressure determinants in over 750,000 individuals' (Nature Genetics, 2019), and 'Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy for prostate cancer patients with unfavourable intermediate-risk or high-risk disease' from the TROG 03.04 RADAR trial (Lancet Oncology, 2019). As an investigator, he has contributed to grants from 2013 to 2023 on topics such as stroke care, Aboriginal health assessments, smoking cessation in pregnancy, and dementia discharge planning. His high-impact publications and collaborations have advanced genetic research, clinical trials, and public health interventions.